Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

CompletedOBSERVATIONAL
Enrollment

4,005

Participants

Timeline

Start Date

May 1, 2016

Primary Completion Date

September 1, 2018

Study Completion Date

March 20, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

PIVKA-II

Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.

Trial Locations (1)

200438

Eastern hepatobiliary surgery hospital, Shanghai

All Listed Sponsors
collaborator

Abbott Diagnostics Division

INDUSTRY

collaborator

Peking University First Hospital

OTHER

collaborator

The First Hospital of Jilin University

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

Gansu Provincial Hospital

OTHER

collaborator

Henan Provincial People's Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Sichuan Provincial People's Hospital

OTHER

lead

Eastern Hepatobiliary Surgery Hospital

OTHER

NCT03047603 - Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC | Biotech Hunter | Biotech Hunter